Cited 0 times in
Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김태임 | - |
dc.contributor.author | 서경률 | - |
dc.contributor.author | 이훈 | - |
dc.date.accessioned | 2015-12-28T11:03:54Z | - |
dc.date.available | 2015-12-28T11:03:54Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0002-9394 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/138616 | - |
dc.description.abstract | PURPOSE: To assess tear cytokine levels and clinical outcomes in moderate and severe meibomian gland dysfunction (MGD) after 2 months of treatment with topical loteprednol etabonate and eyelid scrubs with warm compresses vs eyelid scrubs with warm compresses alone. DESIGN: Randomized controlled trial. METHODS: Patients with moderate and severe MGD were randomized into 2 groups: topical loteprednol etabonate and eyelid scrubs with warm compresses (Group I, 34 eyes) or eyelid scrubs with warm compresses (Group II, 36 eyes). We evaluated cytokine levels, tear film break-up time (TBUT), corneal and conjunctival fluorescein staining, biomicroscopic examination of lid margins and meibomian glands, and the Ocular Surface Disease Index before initiating treatment and 1 month and 2 months after treatment. RESULTS: There were significant decreases in the levels of interleukin (IL)-6, IL-8, and IL-1β in Group I, and IL-6 and IL-8 in Group II. Moreover, the observed decreases of these cytokines in Group I were attributed to a remarkable decrease between treatment and 1 month after treatment. In Group I, there were improvements in all of the clinical outcomes, with prominent improvement in TBUT, corneal and conjunctival fluorescein staining, and meibum quality after 1 month of treatment, compared with Group II. An improvement in meibomian gland expressibility and MGD stage reduction were more remarkable in Group I. CONCLUSIONS: Topical loteprednol etabonate and eyelid scrubs with warm compresses were tolerated and efficacious for the treatment of moderate and severe MGD. We suggest that such beneficial effects could manifest after 1 month. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF OPHTHALMOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Administration, Topical | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Androstadienes/administration & dosage | - |
dc.subject.MESH | Androstadienes/therapeutic use* | - |
dc.subject.MESH | Anti-Allergic Agents/administration & dosage | - |
dc.subject.MESH | Anti-Allergic Agents/therapeutic use* | - |
dc.subject.MESH | Bandages | - |
dc.subject.MESH | Cytokines/metabolism* | - |
dc.subject.MESH | Eye Proteins/metabolism* | - |
dc.subject.MESH | Eyelid Diseases/classification | - |
dc.subject.MESH | Eyelid Diseases/drug therapy* | - |
dc.subject.MESH | Eyelid Diseases/metabolism | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Flow Cytometry | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Loteprednol Etabonate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Meibomian Glands/drug effects* | - |
dc.subject.MESH | Meibomian Glands/metabolism | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Ophthalmic Solutions | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Surveys and Questionnaires | - |
dc.subject.MESH | Tears/metabolism* | - |
dc.title | Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학) | - |
dc.contributor.googleauthor | Hun Lee | - |
dc.contributor.googleauthor | Byunghoon Chung | - |
dc.contributor.googleauthor | Kyu Seo Kim | - |
dc.contributor.googleauthor | Kyoung Yul Seo | - |
dc.contributor.googleauthor | Bong Joon Choi | - |
dc.contributor.googleauthor | Tae-im Kim | - |
dc.identifier.doi | 10.1016/j.ajo.2014.08.015. | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01080 | - |
dc.contributor.localId | A01870 | - |
dc.contributor.localId | A03344 | - |
dc.relation.journalcode | J00097 | - |
dc.identifier.eissn | 1879-1891 | - |
dc.identifier.pmid | 25128594 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0002939414004966 | - |
dc.contributor.alternativeName | Kim, Tae Im | - |
dc.contributor.alternativeName | Seo, Kyuong Yul | - |
dc.contributor.alternativeName | Lee, Hun | - |
dc.contributor.affiliatedAuthor | Kim, Tae Im | - |
dc.contributor.affiliatedAuthor | Seo, Kyuong Yul | - |
dc.contributor.affiliatedAuthor | Lee, Hun | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 158 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1172 | - |
dc.citation.endPage | 1183.e1 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF OPHTHALMOLOGY, Vol.158(6) : 1172-1183.e1, 2014 | - |
dc.identifier.rimsid | 38446 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.